CPIX — Cumberland Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $69.42m
- $66.43m
- $37.87m
- 58
- 39
- 91
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.04 | ||
| Price to Tang. Book | 17.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.63% | ||
| Return on Equity | -24.71% | ||
| Operating Margin | -16.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 37.44 | 35.99 | 42.01 | 39.55 | 37.87 | n/a | n/a | 1.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Directors
- A. Kazimi CHM (62)
- John Hamm CFO (65)
- Martin Cearnal EVP (76)
- Leo Pavliv EVP (60)
- James Herman SVP (65)
- Gordon Bernard IND (69)
- Joseph Galante IND (71)
- Jonathan Griggs IND (86)
- Joey Jacobs IND (67)
- James Jones IND (73)
- Kenneth Krogulski IND (64)
- Caroline Young IND (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 7th, 1999
- Public Since
- August 11th, 2009
- No. of Shareholders
- 93
- No. of Employees
- 91
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 13,968,394
- Address
- 2525 West End Avenue, Suite 950, NASHVILLE, 37203
- Web
- https://www.cumberlandpharma.com/
- Phone
- +1 6152550068
- Auditors
- Carr, Riggs & Ingram, LLC
Upcoming Events for CPIX
Q2 2025 Cumberland Pharmaceuticals Inc Earnings Release
Similar to CPIX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Cumberland Pharmaceuticals share price?
As of Today at 20:07 UTC, shares in Cumberland Pharmaceuticals are trading at $4.97. This share price information is delayed by 15 minutes.
How has the Cumberland Pharmaceuticals share price performed this year?
Shares in Cumberland Pharmaceuticals last closed at $4.97 and the price had moved by +192.35% over the past 365 days. In terms of relative price strength the Cumberland Pharmaceuticals share price has outperformed the S&P500 Index by +169.85% over the past year.
What are the analyst and broker recommendations for Cumberland Pharmaceuticals?
The overall consensus recommendation for Cumberland Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cumberland Pharmaceuticals dividend yield?
Cumberland Pharmaceuticals does not currently pay a dividend.
Does Cumberland Pharmaceuticals pay a dividend?
Cumberland Pharmaceuticals does not currently pay a dividend.
When does Cumberland Pharmaceuticals next pay dividends?
Cumberland Pharmaceuticals does not currently pay a dividend.
How do I buy Cumberland Pharmaceuticals shares?
To buy shares in Cumberland Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cumberland Pharmaceuticals?
As of the previous close price of $4.97, shares in Cumberland Pharmaceuticals had a market capitalisation of $69.42m.
Where are Cumberland Pharmaceuticals shares listed?
Here are the trading details for Cumberland Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CPIX
What kind of share is Cumberland Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Cumberland Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cumberland Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Cumberland Pharmaceuticals is $8.50. That is 71.03% above the last closing price of $4.97.
Analysts covering Cumberland Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Cumberland Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cumberland Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +329.37%.
As of the last closing price of $4.97, shares in Cumberland Pharmaceuticals were trading +97.93% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cumberland Pharmaceuticals PE Ratio?
The Cumberland Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cumberland Pharmaceuticals?
Cumberland Pharmaceuticals' management team is headed by:
- A. Kazimi - CHM
- John Hamm - CFO
- Martin Cearnal - EVP
- Leo Pavliv - EVP
- James Herman - SVP
- Gordon Bernard - IND
- Joseph Galante - IND
- Jonathan Griggs - IND
- Joey Jacobs - IND
- James Jones - IND
- Kenneth Krogulski - IND
- Caroline Young - IND